No connection

Search Results

HYPR vs LLY

HYPR
Hyperfine, Inc.
NEUTRAL
Price
$1.21
Market Cap
$119.2M
Sector
Healthcare
AI Confidence
85%
LLY
Eli Lilly and Company
NEUTRAL
Price
$958.65
Market Cap
$858.01B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
HYPR
--
LLY
41.7
Forward P/E
HYPR
-3.67
LLY
22.78
P/B Ratio
HYPR
2.87
LLY
32.33
P/S Ratio
HYPR
8.79
LLY
13.16
EV/EBITDA
HYPR
-2.33
LLY
27.08

Profitability

Gross Margin
HYPR
49.79%
LLY
83.04%
Operating Margin
HYPR
-144.87%
LLY
44.9%
Profit Margin
HYPR
-262.29%
LLY
31.67%
ROE
HYPR
-79.01%
LLY
101.16%
ROA
HYPR
-40.61%
LLY
19.41%

Growth

Revenue Growth
HYPR
128.0%
LLY
42.6%
Earnings Growth
HYPR
--
LLY
51.4%

Financial Health

Debt/Equity
HYPR
0.01
LLY
1.65
Current Ratio
HYPR
4.34
LLY
1.58
Quick Ratio
HYPR
3.56
LLY
0.78

Dividends

Dividend Yield
HYPR
--
LLY
0.68%
Payout Ratio
HYPR
0.0%
LLY
26.14%

AI Verdict

HYPR NEUTRAL

HYPR presents a high-risk, high-reward profile characterized by a stable Piotroski F-Score of 4/9 and a lack of traditional valuation benchmarks due to negative earnings. The company is experiencing explosive revenue growth (128% YoY) and maintains a strong liquidity position with a Current Ratio of 4.34 and negligible debt. However, these strengths are offset by severe profit margins (-262.29%) and a bearish insider sentiment. The stock is currently a speculative growth play where the market is pricing in future scalability rather than current fundamentals.

Strengths
Explosive revenue growth of 128% YoY
Strong liquidity with a Current Ratio of 4.34
Very low leverage (Debt/Equity of 0.01)
Risks
Severe negative profit margins (-262.29%)
Bearish insider activity with consistent selling by C-suite executives
High valuation relative to sales (P/S of 8.79) for a non-profitable firm
LLY NEUTRAL

LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.

Strengths
Strong profitability (31.7% margin)
Strong revenue growth of 42.6%
Strong ROE of 101.2%
Risks
High valuation with P/E of 41.7
Premium vs Graham Number ($123.85)
Weak financial trend (Piotroski F-Score: 3/9)

Compare Another Pair

HYPR vs LLY: Head-to-Head Comparison

This page compares Hyperfine, Inc. (HYPR) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile